AbbVie, Shire and how $54.7B can turn a 'no' into a 'yes'

It takes finesse to pull off a megadeal. For months, AbbVie ($ABBV) mounted a dogged pursuit of Shire ($SHPG), learning from the mistakes of the now-thwarted Pfizer ($PFE) and maintaining its patience without letting lines go cold, largely avoiding major missteps as it closed in on its target. The New York Times' DealBook has a detailed account of the whole proceedings, culled from interviews with people involved in the negotiations, that paints AbbVie as a clever suitor committed to staying on message and Shire as its realistic counterpart with ears pricked for a magic number. Story (sub. req.)

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.